Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04669522
Other study ID # PHDW-006
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 2020
Est. completion date December 2021

Study information

Verified date December 2020
Source Pius-Hospital Oldenburg
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

It has been established that chronic stress can take a toll on one's health. Furthermore, when an someone falls ill, it is believed that the way that they handle stress and/or adversity can positively or negatively impact the course of their disease. Against the background of these findings, this study aims to explore how (1) cumulative lifetime stress exposure, (2) coping response, (3) perceived social support, and (4) and overall psychological well-being may relate to the oncological outcomes of women diagnosed with triple negative breast cancer (TNBC). Patients treated for TNBC between 01.01.2015-31.12.2019 at the University Clinic for Gynecology at Pius-Hospital Oldenburg will be asked to complete four questionnaires corresponding to the abovementioned psychological aspects. The results of these questionnaires will be analyzed together with the clinical patient data and tumor characteristics (such as type, size, etc.) to explore whether there is a tendency between one or more of the above-mentioned psychosocial aspects and the course of the disease (e.g. a disease recurrence within one year after the initial diagnosis (yes / no), the duration of the disease-free or progression-free period). As there is an existing body of evidence supporting a relationship between stress and the immune system, we expect to see the poorest oncological outcomes in patients who 1) have faced more stressful/adverse life events, 2) those who present inadequate/inappropriate coping skills, 3) report less social support, and 4) poorer overall psychological well-being. If a potential connection between psychosocial factors and the course of the TNBC is identified, further disease specific, it will aid in the development of disease-specific, health-promoting measures to better support this particular patient group. This is of great importance, as TNBC is generally associated with clinically aggressive behavior and a worse prognosis compared to other breast cancer subtypes.


Description:

Triple negative breast cancer (TNBC) is a highly heterogeneous subtype, which exhibits aggressive clinical behavior and generally carries a poor prognosis. As it lacks hormone receptors expression (estrogen and progesterone receptors) and amplification of the Human epidermal growth factor receptor 2 (HER2), targeted therapies are lacking. Thus, the identification of any modifiable factors which may influence the course of the disease is critical both in improving the quality of care and the patient's quality of life. In addition to lifestyle factors, such as diet and exercise habits, psychological factors, such as cumulative lifetime stress, coping response, perceived social support, and overall psychological well-being may also influence cancer progression. While it is known that stress can directly upregulate certain immune mechanisms, it is suspected that a patient's coping response, perceived social support, and general psychological well-being may have an indirect influence on cancer progression via altered health-related behaviors. For example, during stressful periods, alcohol consumption may rise, sleep quality may be diminished, nutritional needs may not be properly met, and exercise may be avoided. As a group, TNBC patients face additional challenges not experienced by other BC patients. Due to the disease's poor prognosis, its relatively new status as a BC subtype (first mention in 2005), and the lack of targeted treatments; patients may experience an increased stress-response following their diagnosis. For instance, it is known that an event induces a stress response when it involves novelty and unpredictability, a lack of sense of control, and threats to the sense of self; elements that are clearly emphasized in TNBC. To promote the development of psycho oncological strategies tailored towards women in this particular patient group, this study aims to explore any trends which might be indicative of an interaction between psychological aspects and the oncological outcomes of patients treated for TNBC between 01.01.2015-31.12.2019, at Pius Hospital, in Oldenburg, Germany. Because we intend to evaluate a retrospective cohort of patients, the psychological instruments were chosen and slightly adapted to target past events (stress across life span and social support) and stable traits (psychological well-being, coping). As there is an existing body of evidence supporting the relationship between stress and the immune system, we expect to see the poorest oncological outcomes in patients who 1) have had more adverse life events, and 2) those who present inadequate/inappropriate coping skills. Additionally, we intend to explore if other psychological variables mentioned in the literature, including perceived social support and psychological well-being, are also related to the oncological outcomes in our cohort of patients. This study combines prospective and retrospective approaches since the psychosociological data is to be collected prospectively from a single retrospective cohort of patients. Patients could not be randomized into groups, due to the retrospective nature of the study. Considering that all data derived from this study will be numerical, this will be a quantitative analysis. This research is comparative since the patients' clinical outcomes will be analyzed in terms of psychological measures. Lastly, the present study is exploratory as it aims to shed light on the interplay between psychological and clinical aspects in TNBC, as psycho-oncological studies are lacking for this BC subtype. A list of patient names will be obtained from the hospital's Tumor Documentation Office. Next, patient electronic medical records will be accessed through Pius-Hospital's Orbis Database program according to the name and date of birth of each patient. Demographic and clinical variables of interest will be collected from the clinical charts and recorded on the patient case report form (CRF). The psychological aspects of interest will be assessed through self-reported questionnaires. (1 computer-based and 3 paper-based questionnaires). Patients will fill out the surveys in a proper setting where privacy will be assured. Questionnaires will not include information which could be directly used to identify participants (i.e. name, DOB), but will instead contain a code which will allow the psychological data to be combined with the respective participant's demographic and clinical variables for the subsequent statistical analysis. After completion, participant's information (pseudonymized) will be transferred to the CRF, and subsequently case data will be transferred to SPSS (software version 26.0) for further statistical analysis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - a confirmed diagnosis of TNBC, with the ability to speak and understand German, who can give informed consent, and who were treated in the University Hospital for Gynecology, Pius-Hospital Oldenburg, between 01.01.2015-31.12.2019 Exclusion Criteria: - 1) any woman with an unconfirmed TNBC diagnosis, 2) woman whose medical records are lacking clinical and/or pathological variables of interest, 3) patients with current or previous mood disorder, psychosis, anxiety disorder, psychosis, anxiety disorder, or substance abuse disorder according to the DSM V, Diagnostic and Statistical Manual of Mental Disorders, and 5) all women who currently make use of psychotropic agents or psychiatric drugs.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Pius-Hospital Oldenburg University of Oldenburg

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Severity Score (OSS) Cumulative lifetime stress will be quantified as a score (Overall Severity Score; OSS) derived from the Stress and Adversity Inventory (STRAIN) questionnaire (Slavich and Shields, 2018). 1 day
Secondary Hazard ratio associated with OSS 1 day
See also
  Status Clinical Trial Phase
Completed NCT04879849 - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Phase 1
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Withdrawn NCT02427581 - Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Phase 1
Not yet recruiting NCT05973864 - Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery Phase 3
Completed NCT02789332 - Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Recruiting NCT05208762 - A Study of SGN-PDL1V in Advanced Solid Tumors Phase 1
Completed NCT01969643 - A Safety Study of SGN-LIV1A in Breast Cancer Patients Phase 1
Terminated NCT04489940 - Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer Phase 2
Not yet recruiting NCT06154109 - Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial Phase 2
Withdrawn NCT02539017 - The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer Phase 2
Recruiting NCT06400472 - A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Phase 1
Terminated NCT02720185 - Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR Phase 2
Completed NCT03092934 - A Study of AK-01 (LY3295668) in Solid Tumors Phase 1/Phase 2
Recruiting NCT04895709 - A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06380816 - A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer Phase 1/Phase 2
Recruiting NCT06157892 - A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03036488 - Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Phase 3
Recruiting NCT06385990 - Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy Phase 2